The GLP-1 Trap represents Steve Hargadon's primary example of what he terms the "Law of Inevitable Exploitation" (L.I.E.) operating within modern medicine. This concept illustrates a systematic pattern where engineered problems are followed by costly pharmaceutical solutions that create long-term dependencies while obscuring future risks through immediate benefits.

The Two-Stage Pattern

Hargadon describes the GLP-1 trap as following a precise two-stage process that exemplifies iatrogenic harm—damage caused by the healer. The first stage involved "the engineering of food past the body's natural stop signals" over several decades. Food manufacturers used "genuine scientific precision" to calibrate "sugar, salt, and fat" to "override satiety" and reach what Hargadon calls the "bliss point"—products engineered to be irresistible that were then "deployed at scale."

The second stage emerged when people who consumed these engineered foods were "blamed for not being able to stop." Rather than addressing the engineered food itself, which "could not be" addressed "because the food is the business model," the medical system introduced "a class of drugs that modify digestion, appetite, and reward, so the body stops pursuing the very products engineered to be irresistible." This creates what Hargadon identifies as the core trap: "The first sale is the bliss point. The second sale is the drug. Both sales are to the same customer."

The Structure of Exploitation

Hargadon emphasizes that the GLP-1 trap operates through exploiting genuine human needs and desires, not fabricated ones. He notes that "the motivation to take these drugs is not stupid and it is not vain" because "being thinner in this culture is genuinely rewarded" and "relief from a daily war with food is a real and significant improvement in quality of life." The drugs deliver "real, immediate, felt benefits," which Hargadon identifies as "precisely the structure of the trap."

According to Hargadon's analysis, "the L.I.E. does not exploit imaginary desires. It exploits real ones, and it does so in ways that are invisible precisely because the short-term wins are real." This invisibility occurs because people experience genuine improvements, making the exploitative nature of the system difficult to recognize.

Hidden Long-Term Costs

The trap's effectiveness relies on obscuring long-term consequences behind immediate relief. Hargadon outlines several concerning long-term effects: "Muscle loss. Bone density loss. Gastrointestinal and pancreatic effects whose full shape is not yet known." He also highlights the issue of dependency, noting that "stopping the drug tends to return the weight and sometimes more."

Perhaps most significantly, Hargadon warns of creating "a generation of users whose bodies will have been chronically signaled for years in ways the trial data could not fully anticipate." He argues that "the attractiveness of the short-term solution is very much tied to a willingness not to think about the long-term cost, and the rest of the information environment is quite good at helping you avoid thinking about it."

Systemic Rather Than Individual Problem

Hargadon explicitly states that the GLP-1 trap does not result from individual malice or incompetence. Instead, he argues that "no one in the chain has to be a villain. The pattern produces itself." Each participant—patient, physician, and pharmaceutical company—responds rationally to their immediate circumstances: patients respond to "real desire," physicians to "real symptom[s]," and companies to "real market" conditions.

The trap emerges from structural incentives rather than conscious conspiracy. As Hargadon explains, "an industry whose revenue scales with interventions will, over time, produce more interventions, and the point at which additional interventions begin producing net harm is not the point at which the industry notices."

Broader Pattern

Hargadon presents the GLP-1 trap as illustrative of a generalizable pattern: "Sell the problem. Sell the patch. Eventually, sell the fix for what the patch did. Each stage presents itself as medicine." This pattern operates as a form of iatrogenesis, building on Ivan Illich's 1975 analysis in Medical Nemesis, which argued that modern medicine had "crossed a threshold past which it produced more suffering than it relieved."

The danger of the GLP-1 trap, according to Hargadon, lies precisely in its effectiveness: "The drug does something. That is the trap. If it did nothing, it would not be dangerous. It is dangerous precisely because it works, in the narrow sense, for a while, and the cost comes due on a slower timescale than the marketing cycle." This temporal mismatch between benefits and costs creates the conditions for systematic exploitation of human vulnerability disguised as medical care.